Benchmark lowered the firm’s price target on Tenon Medical to $3 from $5 and keeps a Speculative Buy rating on the shares. The firm is raising its fully-diluted share count assumptions after updating its models for the 10-K filing, calling out the release of data from post market studies later this year that could help increase market acceptance for the CATAMARAN and accelerate revenue uptake as the next catalyst for the stock.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNON:
- Tenon Medical, Inc. Enhances Board with New Appointment
- Tenon Medical’s Partnership Perils: Navigating Uncharted Waters in Search of Commercial Success
- Tenon Medical appoints Kristine Jacques to board of directors
- Tenon Medical announces results from post-market study of Catamaran system
- Tenon Medical Secures Funding Through Equity Sales and Warrants
